Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
Business

Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177, The Canadian Business Journal

TIVERTON, ON, October 24, 2022 (GLOBE NEWSWIRE) — An international collaboration between Bruce Power, Isogen (a company of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE (ITM) today marks the commercial production of Lutetium-177 announced the start of .

The announcement was celebrated at ITM’s headquarters in Munich, Germany, with representatives of the partnership organizations during a trade mission with Ontario’s Minister for Economic Development, Job Creation and Trade, Vic Fedeli.

The milestone was achieved after the completion of final commissioning and regulatory approval by the Canadian Nuclear Safety Commission, a multi-year effort to install a new Isotope Production System (IPS) at Unit 7 of Bruce Power. It is the culmination of the project. -The kind of achievement of a commercial power reactor with the added capability to commercially produce short-lived medical isotopes.

IPS provides reliable industrial-scale production of Lutetium-177, a medical isotope used for targeted cancer therapy. Lutetium-177 is used to develop precision nuclear medicine that precisely targets malignant cells while sparing surrounding healthy tissue.

“Ontario’s nuclear industry supports thousands of highly skilled jobs and is at the forefront when it comes to innovation,” said Prime Minister Doug Ford. A major step forward as a global leader in isotope production in the fight against cancer.This unique international project, using Made in Ontario infrastructure, will help doctors and patients need it at home and around the world. It will help improve access to life-saving isotopes.”

“We at Bruce Power, together with our partners Isogen, ITM and Saugeen Ojibway Nation, are very proud to celebrate the successful start of commercial operation of the world’s first large-scale isotope production system for the production of Lutetium-177. Mike Rencheck, President and CEO of Bruce Power, said: “This announcement is the result of years of dedication and the work of thousands of employees across this unique international partnership. Thanks to the hard work and innovative spirit of our staff.”

Designed and installed by Bruce Power’s Isogen, the Made-in-Ontario IPS is irradiated with ytterbium-176 to produce lutetium-177, which is then transported to ITM’s manufacturing facility in Germany for pharmaceutical grade carrier doping. not handle lutetium. -177 (nca lutetium-177). ITM supplies medical facilities worldwide with nca lutetium 177, an isotope used in a variety of clinical and commercial radiopharmaceutical cancer treatments .

Kinectrics CEO David Harris said: “This day marks a paradigm shift in medical isotope supply, with the international medical community committing to scalable, reliable, Canadian power reactor-manufactured isotopes for cancer treatment. You can depend on it now.”

IPS leverages Bruce Power’s 24/7 continuous operations to provide a consistent and scalable supply of life-saving isotopes used by physicians to treat cancer patients around the world.

Framatome CEO Bernard Fontana said: “Our shared vision with Kinectrics, our Isogen partner, and Bruce Power working with ITM have led to this important milestone. The design, development, installation and implementation of this ambitious and complex project. I am proud of the team that has worked tirelessly to , and as part of the Framatome Healthcare brand, I am honored to play a key role in ensuring the supply of isotopes, including Lutetium-177, to the global medical community. .”

Commercial operation of IPS will enable large-scale production of lutetium-177. It is a time of growing global demand for these short-lived isotopes. ITM holds a US Drug Master File (DMF) with the FDA for nca lutetium 177 and has marketing authorization in the EU (brand name EndolucinBeta®). ITM has exclusive access to the irradiation services provided by IPS for the production of Lutetium-177 and, using an increased supply of high-quality isotopes from IPS, will be able to provide Meet growing demand.

“As the world’s largest provider of high-quality nca lutetium-177 for cancer therapy, we are constantly expanding our production network to ensure supply and access to hospitals and patients around the world. is a testament to this commitment,” said ITM CEO Steffen Schuster. “This smooth scale-up to commercial production ensures the safe production of our Phase 3 assets and our commitment to targeted radionuclide therapy utilizing our currently approved lutetium-177, we thank our partners for doing.”

Ontario’s Minister of Economic Development, Job Creation and Trade, Vic Fedeli, expressed support for international cooperation and the development of Ontario as a global hub for isotope production and innovation.

“International partnerships like this between Bruce Power, Isogen and ITM are paving the way for future innovation in Ontario’s key sectors,” said Minister Fedeli. “Congratulations to everyone involved in this breakthrough in the production of life-saving medical isotopes! Supply will continue to ensure that he is the leader in his chain.”

Bruce Power collaborates with Saugeen Ojibway Nation to Gamzu Carmine Akoziwin.

“The Gamzook’aamin Aakoziwin project has been in the making for years, but today marks another exciting milestone in its journey to support the global fight against cancer,” said Sogeen First Nation. Chippewas Chief Conrad Richie said. “These medical isotopes are used not only in our communities, but around the world to help patients fighting cancer get treatment.”

Veronica Smith, Chippewas Chief of Nawash Unceded First Nation, said: “By working together through this partnership, we are playing a leading role in the fight against cancer and continue to increase access to essential isotopes for transformative cancer treatments and diagnostics.”

Learn more about how isotopes help keep hospitals safe and help diagnose and treat cancer at www.brucepower.com/isotopes.

About Blues Power
Bruce Power is a power company based in Bruce County, Ontario. We are supported by people. Our 4,200 employees are the foundation of our accomplishments, safely delivering clean, reliable, low-cost nuclear power to families and businesses statewide, saving lives around the world. We are proud to play a role in providing life-saving medical isotopes. Bruce Power works hard to have strong roots in Ontario, committed to preserving the environment and supporting the communities in which we live. Formed in 2001, Bruce Power is a Canadian-owned partnership of TC Energy, OMERS, Power Workers’ Union and The Society of United Professionals. Learn more at www.brucepower.com and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.

About Isogen

Isogen is a joint venture between Framatome and Kinectrics whose mission is to enable the CANDU reactor to produce the medical isotopes needed to treat and diagnose patients with serious illnesses around the world. Isogen’s successful partnership with Bruce Power and ITM enables us to provide the world’s largest and most reliable supply of life-saving, short-lived therapeutic medical isotopes. Learn more at www.isogen.ca and follow us on LinkedIn.

About ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotechnology company, is dedicated to delivering a new generation of highly precise radiomolecular therapeutics and diagnostics for difficult-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and partners through excellence in development, production and global supply. Driven by improving patient benefit in all it does, ITM is committed to a wide range of precision tumors, including his two Phase III trials combining the company’s high-quality radioisotopes with a variety of target molecules. advance the academic pipeline. Leveraging nearly 20 years of pioneering expertise in radiopharmaceuticals, industry leadership and established global networks, ITM provides patients with more effective targeted therapies to improve clinical outcomes and livelihoods. We strive to improve our quality. More information: www.itm-radiopharma.com

ITM Medical Isotopes GmbH, a wholly owned subsidiary of ITM Isotope Technologies Munich SE, has entered into a supply agreement for lutetium-177 with Isogen in 2020.

  • Isotope Production System Begins Commercial Production of Anticancer Drug Lutetium-177


CBJ Newsmaker

Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177, The Canadian Business Journal

Source link Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177, The Canadian Business Journal

Related Articles

Back to top button